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ORIGINAL ARTICLE
A Histone Deacetylase Inhibitor LBH589 Downregulates
XIAP in Mesothelioma Cell Lines Which is Likely
Responsible for Increased Apoptosis With TRAIL
James Symanowski, PhD,* Nicholas Vogelzang, MD,* Leigh Zawel, PhD,† Peter Atadja, PhD,†
Harvey Pass, MD,‡ and Sunil Sharma, MD*
Purpose: Tumor necrosis factor-alpha-related apoptosis-inducing
ligand (TRAIL) is a member of tumor necrosis factor family and it
is important for ligand induced apoptosis in tumor cells. TRAIL has
been shown to be synergistic with a variety of chemotherapies and
targeted agents. In the study, a combination of TRAIL and a histone
deacetylase inhibitor LBH589 was studied in mesothelioma cell
lines.
Experimental Design: Five mesothelioma cell lines and two normal
cell lines were tested for cell growth inhibition and apoptosis using
high-throughput assays in the presence of LBH589, TRAIL and a
combination of the two. Caspase induction was studied and levels of
X-linked inhibitor of apoptosis (XIAP) were tested using Western
blotting. A combination of a direct inhibitor of XIAP was also tested
in combination with TRAIL.
Results: In mesothelioma cell lines, a combination of LBH589 and
TRAIL markedly increased cell growth inhibition and apoptosis
when compared with the effect on normal cell lines. LBH589 and
TRAIL appeared to induce higher levels of caspase 3 and 7 and this
appeared to be closely related to ability of LBH589 to degrade
XIAP. In addition, a direct inhibitor of XIAP was also sensitized
cells to TRAIL apoptosis, providing an indirect confirmation for
XIAP degradation as a possible mechanism of synergy.
Conclusions: In mesothelioma cell lines, LBH589 increases the
sensitivity to TRAIL. In addition, at least partly, the mechanism of
this induction of TRAIL sensitivity is due to LBH589 related
degradation of XIAP. These results provide initial evidence for
testing this combination in clinical trials.
Key Words:Mesothelioma, Histone deacetylase inhibitors, apopto-
sis, Tumor necrosis factor-alpha-related apoptosis-inducing ligand.
(J Thorac Oncol. 2009;4: 149–160)
Tumor necrosis factor-alpha-related apoptosis-inducing li-gand (TRAIL) is a member of tumor necrosis factor
(TNF) superfamily and exhibits antitumor activity in a vari-
ety1,2 of tumor cells.1,2 TRAIL signals primarily through two
receptors—DR4 and DR5 that carry a cytoplasmic death
domain. Upon binding to its receptors, TRAIL induces acti-
vation of caspases 8 and 10 that (in turn) lead to activation of
effector caspases 3, 6, and 7 that are responsible for apopto-
sis. Several factors may be responsible for induction of
TRAIL sensitivity to cancer cells. These include decoy re-
ceptors (DcR1 and DcR2 that lack a functional cytoplasmic
death domain), c-FLIP (which is an inhibitor of activation of
caspase 8 and 10), ability to induce intrinsic or mitochondrial
pathway of apoptosis by cleavage of Bid or activation of
XIAP (XIAP that directly binds and inactivates caspase 3 and
9). Several cancers including pancreatic cancers, neuroblas-
tomas, breast cancer, urothelial cancers demonstrate resis-
tance to effects of TRAIL.3–6 In earlier reports, combinations
of histone deacetylase inhibitors (HDAIs) and TRAIL were
found to demonstrate synergistic activity against leukemia
and prostate cancer cell lines.7,8
Mesothelioma is a malignancy that is rare and is caused
by asbestos exposure. Treatment of mesothelioma is unsatis-
factory and is primarily surgical. A minority of patients,
however, demonstrate long- term disease control with surgery
alone. Chemotherapy remains the mainstay of therapy for
advanced and recurrent mesothelioma. Standard chemother-
apy regimen includes cisplatin and pemetrexed that improve
survival in these patients but are often associated with un-
pleasant toxicities. In addition, there are no approved thera-
pies for patients who fail this particular treatment or cannot
tolerate it. There is some clinical activity of HDAIs in
mesothelioma. In a recently published report, 4 of 13 patients
with mesothelioma demonstrated prolonged stable disease
and two patients had partial responses with suberoylanilide
hydroxamic acid which is a HDAI.9
In the report, we tested a combination of TRAIL and a
novel deacetylase inhibitor LBH589 in a panel of mesothe-
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lioma cell lines. Our results demonstrate that this putative
combination is synergistic across a panel of cell lines. In
addition, a marked down-regulation of XIAP was observed
on treatment with LBH589 which contributed to this synergy
between this inhibitor and TRAIL.
MATERIALS AND METHODS
Cells Lines
Human mesothelioma (NCI-H2452, NCI-H2052, and
MSTO-211H) cancer cell lines were obtained from American
Type Culture Collection (ATCC) (CRL-5946, CRL-5915,
and CRL-2081, respectively). ME13 and ME 16 were gra-
cious gifts from Dr. Pass and are unique mesothelioma cell
lines obtained from patients (NYU School of Medicine, NY,
NY). Normal cell lines were studied and included human
dermal fibroblasts (HDFA) obtained from Sciencell Research
Laboratories (2320) and normal human lung cells (Met5A)
also gifted from Dr. Pass. Cell lines were maintained in a
humidified atmosphere of 95% air and 5% CO2 at 37°C. Cell
lines NCI-H2452, NCI-H2052, and MSTO-211H were grown
in RPMI 1640 Medium (ATCC) medium containing 10%
FBS (Gibco/Invitrogen Corp) and penicillin-streptomycin 1
ml/100 ml (Hyclone). Cell lines ME13 and ME16 were
grown in Dulbecco Modified Eagle Medium/ATCC) medium
containing 5% FBS (Gibco/Invitrogen Corp) and penicillin-
streptomycin 1 ml/100 ml (Hyclone). HDFA cells were
grown in fibroblast medium containing 2% FBS and 1%
penicillin-streptomycin. Met5A cells were grown in Dul-
becco Modified Eagle Medium.
Drugs
TRAIL was obtained commercially (EMD Biosciences).
LBH589 (LBH) and LBW-242 (LBW) were provided by No-
vartis. LBH and LBW stock was prepared in DMSO and
dilutions from stock were conducted in media. Z-V-A-D (OMe)-
FMK (ZVAD) was purchased through R&D Systems
(FMK001). ZVAD stock was prepared in DMSO according to
manufacturer’s instruction at a 20 mM concentration and dilu-
tions from stock were conducted in FBS supplemented media.
MG-132 was obtained from Sigma (C2211) and was dissolved
in DMSO to prepare stock solutions.
Cell Growth Inhibition
Cell Growth Inhibition was assessed using the Cell
Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay
(Promega) which uses the MTS reagent. Metabolically active
cells contain dehydrogenase enzymes which can convert the
MTS into aqueous soluble formazan. The quantity of
formazan product is measured by the amount of absorbance
and is directly proportional to the number of living cells.
Approximately 20 hours before experiments, 3500 cells per
well with 200 l of the appropriate media were plated onto a
96 well tissue culture plate. Cells were allowed to adhere
overnight in a 37°C, humidified, 5% CO2 incubator. Cells
were centrifuged at 500  g for 5 minutes and media was
replaced with appropriate volumes so that various concentra-
tions of chemotherapeutic agents (single and in combination)
could be added. After various exposure times to TRAIL,
LBH, or LBH–TRAIL combinations (sequential and/or con-
current), the plates were retrieved from the incubator and an
MTS assay applied according to protocol. The cells were
allowed to incubate with the assay for 3 hours after which the
absorbance was measured at 490 and 630 nm using the Biotek
Quant plate reader and from which the Delta optical density
was calculated.
Cell Death Detection Assay for Apoptosis
Induced cell death was evaluated using the Cell Death
Detection enzyme-linked immunosorbent assay (ELISA) or
CDD (Roche Applied Science) which quantifies histone com-
plexed DNA fragments released from the cytoplasm after
apoptosis induction. 3500 cells per well with 200 l of the
appropriate media were plated onto a 96 well tissue culture
plate. Cells were allowed to adhere overnight in a 37°C,
humidified, 5% CO2 incubator. Cells were centrifuged at
500  g for 5 minutes and media was replaced. Cells were
treated as a single agent and concurrent combination of the
compounds LBH and TRAIL. Cells were incubated for 6 and
24 hours before beginning the CDD protocol and conducted
according to manufacturer’s instructions. For LBH589 and
MG-132 experiments, cells were treated normally with
LBH589. MG-132 was added for last 6 hours before con-
ducting the CDD assay.
Caspase 3, 7, 8, and 9 Activity Assays
Caspase-Glo 3, 7, 8, and 9 were purchased from Pro-
mega and the assay application was followed according to
protocol. For all caspase assays, approximately 20 hours
before experiments, 3500 cells/well were seeded in 96-well
plates (Greiner Bio-One for luminescence assays). The plates
were retrieved from the incubator after overnight incubation,
spun down at 500 x g for 5 minutes, media removed and
replaced with appropriate volumes so that various concentra-
tions of chemotherapeutic agents could be added. Cells were
treated as a single agent and concurrent combination of the
compounds LBH and TRAIL. The plates were read at expo-
sure time ranging from 1 to 48 hours. Luminescence was
recorded with Bio-Tek FL800 Microplate Fluorescence
Reader and results were recorded as relative light units with
blank subtracted.
Immunoblotting
Histone Acetylation
For histone acetylation immunoblotting, cells were
treated with 100 nM LBH for 48 hours, trypsin-treated,
counted by means of Trypan Blue exclusion then washed
with 1X Phosphate Buffered Saline (PBS) 3 times. Cell
pellets were resuspended in Triton Extraction Buffer (PBS
containing 0.5% Triton X 100, 2 mM phenylmethanesulfonyl
fluoride, 0.02% NaN3) at a cell density of 1  10
7 cells per
ml. Cells were lysed on ice for 10 minutes with gentle mixing
then centrifuged at 4800  g for 10 minutes at 4°C. The
supernatant was discarded, and the cell pellet was washed
with Triton Extraction Buffer a second time. The pellet was
resuspended in 0.2 N HCl at a cell density of 4  107 cells
per ml and the histones were acid extracted overnight at 4°C.
The supernatant containing the histones were collected at
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4800  g for 10 minutes at 4°C and protein concentration
was determined using the BCA assay (Pierce, 23235). Ten
micrograms of the histone extract was run on a 4 to 20%
SDS-PAGE gel (Pierce, 25244) at 100 V, using the Trans-
Blot SD Semi-Dry Transfer System (BioRad, 170-3940) for
30 minutes at 20 V to a 0.2 m nitrocellulose membrane. The
immunoblots were probed with antiacetyl histone H3 anti-
body (0.1 g/ml, Upstate, 06–599) and antiacetyl histone H4
(0.5 g/ml, Upstate, 06–598), washed then incubated with
antirabbit IgG HRP secondary antibody (1:5000, Stressgen,
SAB-300I) for 2 hours at room temperature, then detected
with Pierce Supersignal West Dura, an enhanced chemilumi-
nescent detection system (Pierce, 34075) and the Kodak
Image Station 2000R. The membranes were stripped (Pierce,
21059) and reprobed with rabbit polyclonal Total Histone H3
antibody at (1:1000, Cell Signal, 9715).
Whole Cell Lysis
Cells were treated with 100 nM LBH, 75 ng/ml TRAIL
as single agents and in combination for 6, 24, 48 hours. Cells
were transferred to a centrifuge tube, counted by means of
Trypan Blue exclusion, and washed three times with 1X PBS.
Cells were lysed at 2.5  107 cells/ml with RIPA Buffer
(Sigma, R0278) in the presence of protease inhibitors (Pierce,
78410) and incubated on ice for 30 minutes with gentle
mixing. Lysed cells were centrifuged at 8000  g for 10
minutes and the supernatant was collected to a new tube.
Protein content was determined using the Bradford Assay
(Pierce, 23235). 20 to 40 g of lysate was loaded onto a 12%
or 4 to 20% SDS PAGE gel (BioRad, 161-1120 or 161-1123)
and run for 1 hour at 200 V. Gel was allowed to equilibrate
in Tris Glycine Methanol transfer buffer (Pierce, 28380) for
15 minutes. Proteins were transferred using the Trans-Blot
SD Semi-Dry Transfer System (BioRad, 170-3940) for 60
minutes at 20 V to 0.2 m nitrocellulose membranes. Post-
transfer membranes were washed with 1X PBS  0.05%
Tween and blocked with 1X PBST 3% Non Fat Dried Milk
overnight at 4°C. Membranes were probed with antibodies to
Bcl-2 (2.5 g/ml, EMD Bioscience, PC-68), Bid (1:2000,
Cell Signal, 2762), Cleaved Parp (1:2000, Cell Signal, 9541),
cIAP1 (1:2000, Novartis, gift), GAPDH, (1:2000, Cell Sig-
nal, 2118), p21 (1:2000, Abcam, ab18209), SMAC/Diablo
(1:2000, Stressgen, AAP-465), Survivin (1:2000, Cell Signal,
2803), and XIAP (1:2000, Cell Signal, 2042) then incubated
overnight at 4°C in 1XPBST  3% BSA. After incubation
with the primary antibody, blots were washed in 1X PBST,
15 minutes each time. Membranes were incubated with anti-
rabbit IgG HRP (1:25000, Stressgen, SAB-300J) or anti-
mouse IgG HRP (1:3000, Cell Signal, 7076) in 1X PBST 
3% BSA, 2 hours, room temperature, then washed in 1X
PBST, 15 minutes each time. Proteins were detected with
Pierce Supersignal West Dura, a chemiluminescent detection
system (Pierce, 34075) and imaged with the Kodak Image
Station 2000R.
Protein ELISA Assay
TNF-related apoptosis-inducing-ligand Receptor 1 or
Death Receptor 4 (Trail R1/DR4) and TNF-related apoptosis-
inducing-ligand Receptor 1 or Death Receptor 5 (TRAIL
R2/DR5) levels in cell lysates were quantified using the
TRAIL R1/DR4 ELISA (Diaclone, 850.820.192) and TRAIL
R2/DR5 ELISA (Diaclone 850.830.192) kits. NCI-H2452
cells were treated with 100 nM LBH589 and 75 ng/ml TRAIL
at 6, 24, 48 hours as single agents and in combination in
flasks. The cells were collected, counted by means of Trypan
Blue exclusion, and lysed at 1  107 cells/ml with RIPA
Buffer (Sigma, R0278) in the presence of protease inhibitors
(Pierce, 78410). 50.0 l of sample lysate was diluted in 50 l
of standard diluent and added to the pre-coated plates and
allowed to incubate for 1.5 hours. After incubation, the
protocol was conducted according to manufacturer’s instruc-
tion. The Biotek Quant plate reader was used to measure
absorbance at 450 nm.
Statistical Methods
Cell growth inhibition was analyzed using the median
effect equations.10 Delta optical density for each treated well
was expressed as a fraction of cell viability inhibited com-
pared with the average for the untreated control cells (fa). The
variable log(fa/[1fa]) was regressed on the log of the LBH
concentration. Inhibitory concentrations (IC), based on this
regression equation, were calculated separately for LBH
alone and for the LBH-TRAIL combinations. Data from the
cell death detection and caspase assays were analyzed using
analysis of variance techniques. Analyses were conducted for
each incubation time separately. Multiple comparisons
among treatment groups were tested using Tukey’s test for
equal sample sizes or Tukey–Kramer’s test for unequal sample
sizes.11 For the cell death detection and caspase analyses, the
comparisons of primary interests were for the LBH–TRAIL
combination group compared with the single agent TRAIL and
single agent LBH groups. Statistically significant (p  0.05)
results for these comparisons are annotated on the graphs.
RESULTS
Cell Growth Inhibition
Results from the MTS cell viability assay for single
agent TRAIL (Figure 1, Panels A and B) show moderate
sensitivity to TRAIL for the entire battery of mesothelioma
cell lines tested. After 48 hours of incubation (Panel A), no
dose response was detected for H2052 and the IC35 was
greater than 600 ng/ml in the other four cell lines. An
additional 48 hours of exposure to TRAIL (Panel B) resulted
in more marked dose response curves only for H2452 and
ME16 (IC35  457 and 68 ng/ml, respectively).
Cell growth inhibition results for the LBH–TRAIL
combination are shown in Figure 1 (Panels C–F). Both
concurrent and sequential combinations of TRAIL and LBH
increased cell growth inhibition compared with single agents.
Preincubation with TRAIL followed by the LBH–TRAIL
combination had the greatest inhibitory effect. The most
sensitive cell lines were H2452 (Panel C), ME16 (Panel D),
and MSTO (Panel E). ICs (50% for the sensitive cell lines
and 35% for the more resistant cell lines) for single agent
LBH and the combinations are summarized in Panel F. LBH
treatment in combination with TRAIL (sequentially) reduced
the IC50’s by 42 to 84%. Combining LBH with both pre and
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FIGURE 1. Cell growth inhibitory effect of treatment on mesothelioma cell lines. Cells were treated with tumor necrosis fac-
tor-alpha-related apoptosis-inducing ligand (TRAIL) in concentrations ranging from 20 to 200 ng/ml and incubated for 48
(panel A) or 96 (panel B) hours. Panels C–E, cells were incubated with or without 75 ng/ml TRAIL pretreatment for 24 hours,
were washed and then treated with serial dilutions of 20 to 200 nM LBH (20–400 nM LBH for H2052) for 48 hours alone or
in combination with 75 ng/ml TRAIL. Data shown represent cell growth inhibition relative to cell viability in untreated control
cells. Results represent 5 (Panels A and B), 8 (Panels C and E), or 4 (Panel D) replicates (treatment group means  1 standard
error). Panel F, Inhibitory concentrations (IC) for LBH as a single agent and as part of LBH-TRAIL combinations; nM (IC50s for
H2452, ME16, and MSTO. IC35s for H2052 and ME13).
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concurrent TRAIL further decreased the IC50’s by 83 to
97%. ME13 was a more resistant cell with a maximum
inhibitory effect of approximately 40%. However, evaluation
of the IC’s at the 35% inhibition level showed results similar
to those for the IC50’s in the more sensitive cell lines. The
IC35 was decreased with sequential TRAIL-LBH, and was
further reduced with TRAIL preincubation followed by the
combination. Cell line H2052 was most resistant and was
treated with a higher LBH dose range including 400 nM.
Preincubation with TRAIL resulted in an IC35 that was 45%
of the concentration for LBH alone (82 versus 181 nM). Pre
and concurrent TRAIL further lowered the IC35 by 69%.
Apoptosis
Results for the apoptosis assay are shown in Figure 2.
In the most sensitive cell lines, H2452 (Panel A), ME16
(Panel D), and MSTO (Panel E), analysis of the 6-hour
incubation data showed the combination induced significantly
more DNA fragmentation than single agent LBH at both the
20 and 100 nM concentrations. Similarly, the fold increases
in the combination group were greater than in the 75 ng/ml
single agent TRAIL group, although the differences tended to
be numerical. Comparison of the single agents (TRAIL ver-
sus LBH) was of secondary interest so they were not statis-
tically tested; however, the apoptotic activity was qualita-
tively greater in TRAIL than in single agent LBH. At 24
hours, apoptotic activity tended to be greater in the 20 nM
LBH-TRAIL combination than the single-agent groups in the
sensitive cell lines. The 100 nM LBH-TRAIL combination
resulted in increased apoptosis for H2452 but not for ME16
and MSTO. Treatment in the more resistant cell lines (H2052,
Panel B and ME13, Panel C) did not result in increased DNA
fragmentation at 6 hours. At 24 hours, the combination
induced significantly and markedly greater apoptotic activity
compared with both single agent TRAIL and LBH. The
significant increases occurred in both LBH concentrations in
H2052 and in the 100 nM LBH concentration in ME13.
Caspase Activation
Caspase 3 and 7 analysis results are shown in Figure 3
(Panels A–C). Compared with untreated control cells, there
was marked caspase activation in combination-treated cells
across the entire panel. In the more sensitive cell lines
(H2452, Panel A ME16, Panel B, and MSTO, Panel C), there
was clear induction of caspase activation by TRAIL. This
was accentuated by combination with LBH after only 6 hours
of incubation. In the more resistant cell lines (H2052 and
ME13) single agent TRAIL activation of the caspases was
less evident; however, the combination still showed activa-
tion after 24 hours (data not shown). After 48 hours of
incubation, the combination treatment did not increase
caspase activation compared with the single agents; in fact, in
all five cell lines, caspase activation was significantly greater
with single agent LBH treatment. These results reflect the
results from the cell death detection assay, where the combi-
nation treatment induced synergistic apoptosis earlier in the
more sensitive cell lines.
Activation of caspase 9 (Figure 3, Panels D–F) was
evident by 6 hours in cells treated with single agent TRAIL.
Caspase 9 activity was generally accentuated by combination
with LBH, with cell line H2452 being the exception. These
results suggest that the activation of the 3 and 7 caspases was
due, in part, to the activation of the mitochondrial stress
pathway.
Activation of caspase 8 (data not shown) was observed in
4 of the 5 cell lines test after 1 to 6 hours of exposure. Nomarked
increase in luminescence was observed in cells treated with
LBH, nor was the caspase activation accentuated by the LBH–
TRAIL combination. Unfortunately, in this study, caspases ac-
tivation was not studied in the normal cell lines.
Immunoblots and Protein ELISA Assays
Histone Acetylation
As expected, robust acetylation of histone H3 was
observed using LBH589 (Figure 4, Panel A). Parallel to this,
activation of p21 was also seen in mesothelioma cell lines
(data not shown). This was important since this indicated that
cell growth inhibition and apoptosis seen in mesothelioma
cell lines with LBH589 alone was at physiologic concentra-
tions.
PARP Cleavage
PARP, which is cleaved by caspase 3 and 7, was
activated in treated cells (Figure 4, Panel B). This activation
was clearly most evident in the cells treated with the LBH–
TRAIL combination.
Bid Cleavage
Since Bid is an important protein that connects the
intrinsic and extrinsic pathways of apoptosis, we studied the
effects of drug treatments on cleavage of Bid. Figure 4, Panel
B shows that Bid cleavage was observed in cell lines in
combination with TRAIL in most cell lines indicating that
extrinsic and intrinsic pathways of apoptosis are activated
with these combinations. It is interesting that single agent
LBH589 did cause BID cleavage in some cell lines (2052 and
H2452) but this did not depend on sensitivity of these cell
lines to LBH589. The increased apoptosis observed for the
combination in the two cell lines is probably not dependent
on Bid cleavage because onset of cleavage was late (6 hour
data not shown, did not reveal BID cleavage).
XIAP Levels
In all cell lines, compared with controls, cells treated
with 100 nM LBH showed down-regulation of XIAP (Figure
4, Panel C) after 24 hours of exposure. The decline was more
pronounced in H2452, ME13, and MSTO than in ME16 and
H2052. It was not possible to accurately assess the total
magnitude of this decline. However, there is clear reduction
of the signal across all cell lines. This reduction was concor-
dant with peak activation of caspases 3 levels and preceded
cell growth inhibition and apoptosis synergy seen with the
combination at 6 to 24 hours.
ELISA Assays for DR4 and DR5 Receptors
Examination of 6 to 48 hour profiles provided no
evidence that single agent LBH increased the number of
death receptors 4 or 5 (Figure 4, Panel D).
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FIGURE 2. Effect of treatment on apoptosis in mesothelioma cell lines as measured by cell death detection enzyme-linked
immunosorbent assay (ELISA). Cells were treated with 75 ng/ml tumor necrosis factor-alpha-related apoptosis-inducing ligand
(TRAIL) (T), 20 nM LBH (L20), 100 nM LBH (L100), or LBH-TRAIL combinations and incubated for 6 or 24 hours. Data shown
are the ratio of delta optical density (OD) in the treated wells relative to average delta OD in untreated control cells (fold in-
crease). Results represent four replicates for the control and single agent LBH groups and three replicates for the single agent
TRAIL and combination groups (treatment group means  1 standard error). # indicates delta OD in the combination group
significantly different from TRAIL, and * indicates statistical significance versus LBH.
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FIGURE 3. Effect of treatment on caspase activation. Panels A–C, caspase 3/7 activation. Panels D–F, caspase 9 activation.
Cells were treated with 75 ng/ml tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL), 100 nM LBH, or the
concurrent LBH-TRAIL combination and incubated for 1, 3 (caspase 3/7 only), 6, 24, or 48 hours. Results represent 6 (caspase
3/7) or 4 (caspase 9) replicates (treatment group means  1 standard error). # indicates luminescence in combination group
significantly different from TRAIL, and * indicates statistical significance versus LBH.
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FIGURE 4. Effect of treatment on protein
expression, qualified through immunoblots or
protein enzyme-linked immunosorbent assay
(ELISA). Panel A, cells were treated with 100
nM LBH for 48 hours and histones were ex-
tracted and quantified as previously de-
scribed. The vehicle control samples exhibited
little or no acetylation when probed with
acetyl H3 and acetyl H4 whereas the LBH
treated samples exhibited acetylation when
probed with the same. The samples were
probed with total H3 to verify loading. Panel
B, cells were treated as a single agent and
concurrently with 100 nM LBH, 75 ng/ml tu-
mor necrosis factor-alpha-related apoptosis-
inducing ligand (TRAIL) for 24 hours. Whole
cell lysis immunoblots were performed as pre-
viously described. Samples were probed with
Bid/Cleaved Bid and Cleaved Parp. Panel C,
cells were treated with 100 nM LBH for 6, 24,
and 48 hours. An apparent decrease in
X-linked inhibitor of apoptosis (XIAP) is ob-
served at 24 and 48 hours. The blots were
probed with GAPDH as a loading control.
Panel D, cells were treated with 75 ng/ml
TRAIL, 100 nM LBH, or the concurrent LBH-
TRAIL combinations and incubated for 6, 24,
or 48 hours. Results represent the average of
two aliquots from a single replicate 1 stan-
dard error.
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Co-Treatment of Mesothelioma Cells with a
Novel XIAP Inhibitor (LBW) and LBH
LBW242 is a Smac mimetic compound with IC50
values of 200 nM and 5 nM versus XIAP and CIAP1,
respectively, as measured in a Smac peptide competitive
ELISA.12 By multiple criteria including PARP cleavage,
DNA fragmentation, and rescue with zVAD, LBW242 was
shown to induce apoptosis in vitro in cancer cell lines.12 We
used this novel XIAP antagonist to try to recapitulate the
effects of LBH589 in combination with TRAIL (Figure 5,
Panel A). LBW alone (concentrations from .01 to 50 M)
failed to inhibit cell growth in the most sensitive cell line
tested (H2452). However, in combination with 75 ng/ml
TRAIL, 50 M LBW inhibited approximately 50% cell
growth.
Effect of Caspase Inhibitor on the Induction of
TRAIL Sensitivity by LBH
We pretreated H2452 cells with a pan-caspase inhibitor
(ZVAD) before the addition of LBH and TRAIL and ob-
served total abrogation of the cell-growth inhibitory effect of
TRAIL and only a partial abrogation of the LBH effect
(Figure 5, Panel B). In this experiment, single agents LBH
and TRAIL (0 M ZVAD) inhibited approximately 45% and
35% cell growth, respectively. Pretreatment with the lowest
concentration of ZVAD resulted in no cell growth inhibition
in TRAIL-treated cells. In LBH-treated cells, the cell growth
inhibition decreased in a ZVAD dose responsive fashion and
decreased to approximately 20% at 100 M ZVAD.
Effect of LBH and TRAIL on Normal Cell Lines
The effects of LBH and TRAIL treatment on normal
cell lines are shown in Figure 6. The lung tissue cell line
(Met5A) showed minimal cell growth inhibition associated
with LBH treatment alone or in combination with TRAIL (the
IC50’s exceeded 1000 nM, Panel A). The apoptosis assay
(Panel B) showed no activity at 6 hours but did show
increased DNA fragmentation at 24 hours in the LBH–
TRAIL combinations (20 and 100 nM LBH). Cell growth
was inhibited in the human fibroblast cell line (HDFA, Panel
A); the IC50’s were 89 and 76 nM for LBH alone and in
combination with TRAIL, respectively. However, the apo-
ptosis assay showed no activity at 6 or 24 hours (Panel C).
Effect of a Proteasomal Inhibitor (MG-132) on
Apoptosis in Combination with LBH589
We examined the effect of MG-132 in combination
with LBH589. In this experiment, two doses of LBH589 (20
and 500 nM) were used against H2452 cells for a period of 24
hours. MG-132 was added in the last 6 hours of the experi-
ment. Results show that there was a partial reduction in cell
death with this incubation, possibly as a result of slowed
degradation of XIAP by this pathway (data included in
manuscript in preparation).
DISCUSSION
Mesothelioma is an aggressive cancer of pleural and
peritoneal cavities that carries a grave prognosis. Although
rare, its incidence is increasing probably because of wide-
spread asbestos exposure. In a recent review13, it was esti-
mated that there would be 72,000 new cases in US in the next
40 years. However, the epidemic is likely not to peak in
Europe till 2015 (with an estimated 250,000 cases over the
same time period) and will peak later in Asia with larger
numbers of patients.
FIGURE 5. Recapitulation of LBH effect with X-linked inhibitor of apoptosis (XIAP) antagonist LBW242 and abrogation of tu-
mor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) effect with pan-caspase inhibitor in cell line H2452. Panel
A, cells were then treated with .01, .05, .1, 1, 5, 10, and 50 M LBW242 as a single agent and concurrently with 75 ng/ml.
Cells were incubated for 96 hours before beginning the CGI protocol which was performed according to manufacturer’s in-
struction with a 3-hour incubation after addition of the MTS reagent. Panel B, cells were pretreated with 5, 50, or 100 M
ZVAD for 2 hours then treated as a single agent or in combination with either 75 ng/ml TRAIL or 200 nM LBH. Cells were in-
cubated for 48 hours before beginning the CGI protocol which was performed according to manufacturer’s instruction with a
3-hour incubation after addition of the MTS reagent.
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In Stage I mesothelioma (tumor restricted to parietal
pleura), surgery can be an option but usually involved an
extrapleural resection which carries a high mortality and
morbidity.14 Moreover, most patients are not candidates for
aggressive resections because of advanced disease or comor-
bid conditions. Chemotherapy remains the mainstay of ther-
apy for mesothelioma. A combination of cisplatin and pem-
etrexed was shown to be superior to cisplatin alone in a
pivotal study.15 In this trial, the combination therapy exhib-
ited superior response rates, overall survival and quality of
life compared with single agent therapy and is now consid-
ered standard of care for this disease. However, the median
survival (in spite of chemotherapy) is 12.1 months. In addi-
tion, chemotherapy can be associated with severe side effects.
These include myelosuppression, neuropathy, renal dysfunc-
tion, rash, fatigue, etc. In addition, there are no approved
agents for treatment of mesothelioma once patients recur after
chemotherapy response, fail to respond to therapy or are not
candidates for this treatment.
HDAIs have shown clinical activity against mesotheli-
oma. In an initial study, Krug et al.9 described 13 patients
with mesothelioma that were treated on a phase I trial of
FIGURE 6. Effect of treatment on cell growth inhibition (Panel A) and apoptosis (Panels B and C) in normal cell lines. Panel
A, cells were treated with serial dilutions of 20 to 200 nM LBH for 48 hours alone or in combination with 75 ng/ml tumor ne-
crosis factor-alpha-related apoptosis-inducing ligand (TRAIL). Data shown represent cell growth inhibition relative to cell viabil-
ity in untreated control cells. Results represent six replicates (treatment group means  1 standard error). Panels B and C, cells
were treated with 75 ng/ml TRAIL (T), 20 nM LBH (L20), 100 nM LBH (L100), or LBH-TRAIL combinations and incubated for
6 or 24 hours. Data shown are the ratio of delta optical density in the treated wells relative to average delta optical density
(OD) in untreated control cells (fold increase). Results represent four replicates for the control and single agent LBH groups
and three replicates for the single agent TRAIL and combination groups (treatment group means  1 standard error). # indi-
cates delta OD in combination group significantly different from TRAIL, and * indicates statistical significance versus LBH.
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suberoylanilide hydroxamic acid, which is a hydroxamate
(like LBH589 used in this report). In the study, a total of 13
patients were treated with mesothelioma. Two patients had
partial responses and four patients demonstrated prolonged
stable disease. A larger randomized phase II trial is underway
to test the activity of this agent in mesothelioma.
Recombinant TRAIL and several TRAIL- mietic antibod-
ies are in Phase I trials in humans. Preliminary results indicate
safety for these modalities with occasional response to treat-
ment. However, it appears that optimal therapy with these agents
would require combination treatment with other agents.
The precise mechanism of activity of HDAIs remains
elusive. There is general agreement that there are several
favorable antitumor effects seen with these agents. Microar-
ray analysis reveals down-regulation of Insulin-like growth
factors–1, caspase inhibitors, DNA repair enzymes, etc on
therapy for cancer cell lines with HDAC inhibitors.16,17
HDAIs may also acetylate important proteins directly on
lysine residues leading to modification of functional activity.
These include p53, RelA, GATA1 and FoxO3A, nuclear
import protein importin-7, signaling protein -catenin,
DNA repair enzyme K70, and the cytoskeletal protein -tu-
bulin.18 In addition, HDAIs may acetylate heat shock pro-
tein-90 (hsp-90) and disrupt its chaperone function. This may
destabilize several oncogenic proteins like akt, c-raf leading
to favorable antitumor effects.19
In the report, we demonstrate that there is increased cell
growth inhibition and apoptosis when a deacetylase inhibitor
LBH589 is combined with TRAIL. To fully characterize this
phenomenon, we used a panel of five mesothelioma cell lines
in addition to normal cells. In most cell lines, there was
marked activity seen with the combination in multiple assays.
These included cell growth inhibition assays and apoptosis
assays (DNA fragmentation and PARP cleavage). Potentially,
this study leads to higher confidence that there may be
clinical activity observed when these agents are combined in
patients although it is difficult to translate in vitro findings
directly to patients.
We looked at a variety of potential mechanisms that may
explain this increased activity of the combination. We observed
histone acetylation induced reliably using LBH589 as early as 6
hours in mesothelioma cell lines. In addition, p21 was induced
as expected using this inhibitor at an early stage leading to cell
cycle arrest. LBH589 induced robust activation of caspase 3 and
7 but there was significantly higher induction of these caspases
when a combination with TRAIL was employed. Similarly,
caspase 8 and 9 were induced (as predicted) with TRAIL
therapy but significantly greater change in induction was ob-
served with caspase 9 only.
Because Inhibitors of apoptosis (IAPs) are important
regulators of caspase activity, we studied the effects of
combination therapy on these proteins. We studied survivin,
cIAP, and XIAP protein modulation using Western blotting.
We did not find reliable modulation of any of these members
of IAP family except XIAP. However, we observed reliable
and reproducible decrease in XIAP levels across multiple cell
lines in response to LBH589 therapy. Levels of CIAP-1,
Survivin, Smac-Diablo are unaffected by the combination in
these cell lines (Data not shown).
XIAP is a member of IAP family and is involved in
inactivation of caspases 3, 7, and 9. XIAP directly inactivates
these caspases20 although it may also participate in their
polyubiquitnation which has not been confirmed in vivo. In
recently published intriguing studies, it has been suggested
that BIR domains within IAPs must contain both of the
caspase-binding elements that are found in XIAP—the IBM
interacting groove exosite and an inhibitory element—to
inhibit caspase activity.21,22 Thus, most IAP family members
lack these two elements required for caspase inhibition.
However, XIAP might emerge as the dominant inhibitor of
caspases 3, 7, and 9. Our studies seem to support the idea that
down-regulation of XIAP by LBH589 or direct inhibition by
a SMAC mimetic peptide can sensitize TRAIL activity in
mesothelioma cells. Since XIAP may be degraded by protea-
somal degradation, it is interesting that a proteasomal inhib-
itor could partially rescue cells from cell death in combina-
tion with LBH589.
In recent reports, XIAP levels have been found to be
elevated in mesothelioma. In the first report, XIAP was
up-regulated in mesothelioma effusions and peritoneal me-
sotheliomas, suggesting a prosurvival role in malignant me-
sothelioma cells, particularly at these anatomic sites.23 Higher
XIAP expression and Ki-67 score were also associated with a
trend for poor overall survival (p  0.064 for both) in the
univariate analysis. In another report,24 higher levels of XIAP
was found in body cavity effusions and washes of patients
with mesothelioma as compare with normal cells. Several
studies have now indicated that higher levels of XIAP may
contribute to drug resistance to chemotherapy and TNF- in
cells with mesothelioma.25,26
In summary, in the report we demonstrate that TRAIL
activity against mesothelioma can be enhanced significantly
with combination with a HDAC inhibitor LBH589. It also
appears that the mechanism of this induced sensitivity is likely to
be (in part) related to decrease in XIAP levels induced by
LBH589. The exact mechanism of this decrease is not clear and
could be related to direct degradation of XIAP by LBH589 or
decrease in XIAP gene expression. Since XIAP may be impor-
tant for chemotherapy resistance and TNF-a resistance, using
LBH589 or other HDAC inhibitors could be an important
strategy for overcoming such resistance.
There are several caveats to this current report. For exam-
ple, we could not reliably measure CIAP-1 expression because
of difficulty with reliable antibodies. However, CIAP-2 and
survivin levels were not reliably altered in mesothelioma cell
lines by action of LBH589. In addition, we measured levels of
DR4 and DR5 (which were unchanged) but did not measure
levels of all TRAIL interactive proteins e.g., FLIP and FADD
which could be affected in these experiments. Wemeasured pro-
and antiapoptotic proteins e.g., Bcl-2, Bcl-xl and Bim and did
not find reliable differences in these proteins across cell lines.
The enhancement of TRAIL apoptosis by inhibition of histone
deacetylase in mesothelioma cell lines has been previously
reported.27 Subapoptotic doses of suberohydroxamic acid in-
creased TRAIL apoptosis compared with TRAIL alone in two
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phenotypically different mesothelioma cell lines. The authors
showed the antiapoptotic protein Bcl-xl was down-regulated by
the combined treatment. However, we have now shown that
there is an additional mechanism for this down-regulation. In our
study, we have carefully studied the timing of the apoptosis and
its relationship to caspases activation and XIAP down-regula-
tion. In addition, our study tests a large number of commercially
available cell lines in addition to uniquely derived cell lines from
mesothelioma patients. We also provide secondary validation
for XIAP mechanis by utilizing alternative smac- mimetic pep-
tides to recapitulate this effect. We do not observe any modu-
lation of Bcl-xl in these cell lines that could explain this synergy.
Part of the difference in our study may stem from different
HDAC inhibitors used (LBH589 is in human trials and is several
logs more potent than suberohydroxamic acid used in the prior
study) and frommethodology and cell lines used. In addition, we
were careful not to report significant differences unless they
were striking and observed across cell lines. In spite of this
methodology, it is possible that variations in the effects across
cell lines can be better classified according to histologic sub-
types. However, our sample size was too small to properly
examine this possibility.
Other pathways e.g., stress response pathway (e.g.,
protein 3-phosphoinositidedependent kinase 1) may be im-
portant for modulation of TRAIL sensitivity in mesothelioma
cell lines.28 These and other pathways were not the focus of
this report and were not examined.
In summary, there appears to be significant induction of
TRAIL sensitivity by HDAIs in mesothelioma cell lines. This
increased activity of the combination appears to be (at least in
part) related to a HDAI mediated degradation of XIAP. It
appears that this modulation of XIAP can be observed across
many cell lines and is recapitulated using direct inhibitors of
XIAP (e.g., SMAC mimetics). Potentially, the use of HDAC
inhibitors to synergize with chemotherapy or TRAIL like agents
or usage of direct inhibitors of XIAP to serve the same purpose
may be important therapeutic strategies for mesothelioma.
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